Retrieved 11 April Precautions should be taken in people with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics along with other medications that affect blood sugar levels and should be monitored regularly for worsening of glucose control. This study aimed to determine the relationship between dopamine receptor occupancy by aripiprazole and change in working memory in patients with schizophrenia. Cite this article Shin, S.
Dopamine partial agonism and functional selectivity have been innovative strategies in the pharmacological treatment of schizophrenia and mood disorders and have shifted the concept of dopamine modulation beyond the established approach of dopamine D2 receptor D2R antagonism. The complexity of the mechanism of action has progressively shifted the conceptualization of this agent from partial agonism to functional selectivity. From the induction of early genes to modulation of scaffolding proteins and activation of transcription factors, aripiprazole has been shown to affect multiple cellular pathways and several cortical and subcortical neurotransmitter circuitries. Growing evidence shows that, beyond the consequences of D2R occupancy, aripiprazole has a unique neurobiology among available antipsychotics. The effect of chronic administration of aripiprazole on D2R affinity state and number has been especially highlighted, with relevant translational implications for long-term treatment of psychosis. The hypothesized effects of aripiprazole on cell-protective mechanisms and neurite growth, as well as the differential effects on intracellular pathways [i. This review aims to recapitulate the main neurobiological effects of aripiprazole and discuss the potential implications for upcoming improvements in schizophrenia therapy based on dopamine modulation beyond D2R antagonism. In its simplest form, the dopaminergic hypothesis states that an increase in dopamine release in the striatum possibly as a final consequence of multiple receptor aberrant interactions is associated with a reduced dopaminergic tone in the dorsal prefrontal cortex [ 2 ].
Improving the treatment of schizophrenia: focus on serotonin 5-HT 1A receptors. Acta Psychiatrica Scandinavica. BMC Psychiatry. Eur J Pharmacol. Aripiprazole has been approved by the FDA for the treatment of dopamlne acute manic and mixed episodes, in people older than 10 years. J Med Chem. Pharmacol Res. However, these effects do not last after chronic aripiprazole administration [ 88 ].